Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market definitions
1.3 Base estimates and calculations
1.4 Forecast calculations
1.5 Data sources
1.6 Data validation
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Urinary Retention Therapeutics industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Drug class trends
2.1.3 Incontinence type trends
2.1.4 Distribution channel trends
2.1.5 Regional trends
Chapter 3 Urinary Retention Therapeutics Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of urinary incontinence (UI)
3.2.1.2 Rising geriatric population across the globe
3.2.1.3 Growing awareness about the benefits of early diagnosis and treatment
3.2.1.4 Development of new and innovative treatment options
3.2.1.5 Growing demand for home-based care
3.2.2 Industry pitfalls & challenges
3.2.2.1 Availability of alternate treatment options
3.2.2.2 Side effects of medication
3.3 Growth potential analysis
3.3.1 By drug class
3.3.2 By incontinence type
3.3.3 By distribution channel
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Technology landscape
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Competitive dashboard, 2022
4.3 Company matrix analysis, 2022
4.4 Company market share analysis, 2022
4.5 Competitive positioning matrix, 2022
4.6 Strategic outlook matrix, 2022
Chapter 5 Urinary Retention Therapeutics Market Estimates and Forecast, By Drug Class (USD Million)
5.1 Key trends, by drug class
5.2 5-alpha-reductase inhibitor and alpha-blocker drugs
5.3 Anticholinergic/antispasmodic agents
5.4 Antidepressants
5.5 Skeletal muscle relaxants
5.6 Topical estrogens
5.7 Other drugs
Chapter 6 Urinary Retention Therapeutics Market Estimates and Forecast, By Incontinence type (USD Million)
6.1 Key trends, by incontinence type
6.2 Stress incontinence
6.3 Urge incontinence
6.4 Over-flow incontinence
6.5 Mixed incontinence
6.6 Other incontinence types
Chapter 7 Urinary Retention Therapeutics Market Estimates and Forecast, By Distribution Channel (USD Million)
7.1 Key trends, by distribution channel
7.2 Retail pharmacy
7.3 Hospital pharmacy
7.4 Online pharmacy
Chapter 8 Urinary Retention Therapeutics Market Size and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Merck KGaA
9.2 Sanofi
9.3 Sun Pharmaceutical Industries Ltd.
9.4 Pfizer Inc.
9.5 GlaxoSmithKline plc.
9.6 Eli Lilly
9.7 Astellas Pharma Inc.
9.8 Bayer AG
9.9 Johnson & Johnson
9.10 Novartis AG
